CRSP CRISPR Therapeutics AG
FY2025 10-K
CRISPR Therapeutics AG (CRSP) filed its fiscal year 2025 10-K annual report with the SEC on Feb 12, 2026. This page provides AI-powered analysis of the filing, including business overview, management discussion, risk factors, and key financial metrics from XBRL data.
AI Filing AnalysisFY2025 10-K
Business Overview
- • Core business: Development and commercialization of transformative CRISPR/Cas9 gene-editing therapeutics for serious diseases including hemoglobinopathies, in vivo editing, CAR T therapies, and regenerative medicine
- • New emphasis: First approved CRISPR-based therapy CASGEVY launched globally in 2023 for sickle cell disease and beta thalassemia, with ongoing pediatric trial expansions and targeted conditioning research
Management Discussion & Analysis
- • No revenue or YoY revenue figures disclosed for 2025 vs 2024
- • Operating cash flow used $345.0M in 2025 vs $142.8M in 2024, $202.2M increase due to timing of Vertex milestone payments
Risk Factors
- • Regulatory risk: FDA final guidance "Human Gene Therapy Products Incorporating Human Genome Editing" issued January 2024 may require additional testing or data
- • Macroeconomic threat: Increased CASGEVY development and commercialization costs starting 2025 exceed revenue share, impacting financial position
Financial SummaryXBRL
Revenue
$4M
Net Income
-$582M
Operating Margin
-18933.6%
Net Margin
-16569.8%
ROE
-30.3%
Total Assets
$2.3B
EPS (Diluted)
$-6.47
Operating Cash Flow
-$345M
Source: XBRL data from CRISPR Therapeutics AG FY2025 10-K filing on SEC EDGAR. All figures in USD.
Get deeper insights on CRISPR Therapeutics AG
Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.